# US 2022/0017900 A1 · Methods of cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017900 A1
- Document ID: US20220017900A1
- Status: Published application
- Kind: A1
- Application number: 17/312,362
- Filed: 2019-12-09
- Published: 2022-01-20
- Earliest claimed: 2018-12-10
- Assignees: Cambridge Enterprise Limited
- Applicants: Cambridge Enterprise Limited
- Inventors: Arthur Kaser; Zaeem Cader
- Web page: https://patentgrep.com/patent/US20220017900A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/52: Purines, e.g. adenine
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/708: having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- A61K 40/46: Viral antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C12Q 1/48: involving transferase
- G01N 33/573: for enzymes or isoenzymes
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/531: Stem-loop; Hairpin
- G01N 2333/91142: Pentosyltransferases (2.4.2)
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention relates to the finding that inhibition or inactivation of FAMIN (‘fatty acid metabolism-immunity nexus’; C13orf31; LACC1 (laccase domain containing 1)) reduces tumourigenesis and stimulates cell-mediated immune responses. Method of treating cancer or stimulating cell-mediated immune responses in an individual by reducing FAMIN activity in the individual are provided. Also provided are methods of activating T cells in vitro using FAMIN deficient immune cells and stimulating cell-mediated immune responses comprising administering (a) a population of FAMIN deficient immune cells; or (b) a population of T cells activated in vitro by a population of FAMIN deficient immune cells.

## Claims

### Claim 1

A method of treating cancer in an individual in need thereof comprising reducing FAMIN activity in the individual.

### Claim 2

A method of stimulating a cell-mediated immune response in an individual in need thereof comprising reducing FAMIN activity in the individual.

### Claim 3 (depends on 2)

A method according to claim 2 wherein the individual has cancer and the method is a method of cancer immunotherapy.

### Claim 4 (depends on 2)

A method according to claim 2 wherein the individual has an infection and the method is a method of immunotherapy.

### Claim 5

A method according to any one of the preceding claims wherein the method comprises administering an agent which reduces FAMIN activity to the individual.

### Claim 6 (depends on 5)

A method according to claim 5 wherein the agent is a FAMIN antagonist.

### Claim 7 (depends on 6)

A method according to claim 6 wherein the FAMIN antagonist is an organic compound having a molecular weight of 900 Da or less.

### Claim 8 (depends on 7)

A method according to claim 7 wherein the FAMIN antagonist comprises 3′-deoxy-N-(1-oxododecyl) adenosine, pentostatin, EHNA, 8-aminoguanosine, MT-ImmA or MT-DADMe-ImmA (MTDIA) or a pharmaceutically acceptable salt, solvate, or derivative of any one of these.

### Claim 9 (depends on 5)

A method according to claim 5 wherein the agent is a suppressor nucleic acid that reduces expression of active FAMIN polypeptide.

### Claim 10 (depends on 9)

A method according to claim 9 wherein the suppressor nucleic acid is a siRNA or shRNA.

### Claim 11 (depends on 10)

A method according to claim 10 wherein the suppressor nucleic acid comprises a nucleotide sequence at least 95% identical to a contiguous sequence of 15 to 40 nucleotides of SEQ ID NO: 2.

### Claim 12 (depends on 9)

A method according to claim 9 wherein the suppressor nucleic acid is an antisense oligonucleotide.

### Claim 13 (depends on 5)

A method according to claim 5 wherein the agent is a targeted nuclease that reduces expression of active FAMIN polypeptide to the individual.

### Claim 14 (depends on 13)

A method according to claim 13 wherein the targeted nuclease is a ZFN, TALEN or meganuclease that recognises a target sequence within the FAMIN gene.

### Claim 15 (depends on 13)

A method according to claim 13 wherein the targeted nuclease is a CRISPR associated nuclease, said CRISPR associated nuclease being administered in combination with a guide RNA that recognises a target sequence within the FAMIN gene.

### Claim 16 (depends on 14, 15)

A method according to claim 14 or claim 15 wherein the targeted nuclease cleaves genomic DNA at the target sequence of the FAMIN gene, thereby causing a deletion or insertion which reduces expression of active FAMIN polypeptide.

### Claim 17 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method according to any one of claims 5 to 16 wherein the agent is administered in combination with an additional therapeutic agent.

### Claim 18 (depends on 17)

A method according to claim 17 wherein the additional therapeutic agent is an immune checkpoint inhibitor.

### Claim 19 (depends on 18)

A method according to claim 18 wherein the additional therapeutic agent is an anti-cancer agent.

### Claim 20 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

An agent which reduces FAMIN activity for use in a method according to any one of claims 5 to 19.

### Claim 21 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

Use of an agent which reduces FAMIN activity in the manufacture of a medicament for use in a method according to any one of claims 5 to 19.

### Claim 22 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A pharmaceutical composition comprising an agent as defined in any one of claims 5 to 20 in combination with an additional therapeutic agent, and further comprising a pharmaceutically acceptable excipient.

### Claim 23 (depends on 22)

A pharmaceutical composition according to claim 22, wherein the additional therapeutic agent is an anti-cancer agent.

### Claim 24

A method of stimulating cell-mediated immune responses comprising administering to an individual in need thereof;
(a) a population of FAMIN deficient immune cells; or
(b) a population of T cells activated in vitro by a population of FAMIN deficient immune cells.

### Claim 25 (depends on 24)

A method according to claim 24 wherein the individual has cancer and the method is a method of cancer immunotherapy.

### Claim 26 (depends on 24)

A method according to claim 24 wherein the individual has an infection and the method is a method of immunotherapy.

### Claim 27 (depends on 24, 25, 26)

A population of FAMIN deficient immune cells; or a population of T cells activated in vitro by a population of FAMIN deficient immune cells for use in a method according to any one of claims 24 to 26.

### Claim 28 (depends on 24, 25, 26)

Use of a population of FAMIN deficient immune cells; or a population of T cells activated in vitro by a population of FAMIN deficient immune cells for use in in the manufacture of a medicament for use in a method according to any one of claims 24 to 26.

### Claim 29

An in vitro method of activating T cells comprising;
providing a population of naïve T cells,
culturing the T cells with a population of FAMIN deficient immune cells,
thereby producing an activated T cell population.

### Claim 30 (depends on 29)

A method according to claim 29 wherein the immune cells display a target antigen and the activated T cell population are specific for the displayed target antigen.

### Claim 31 (depends on 29, 30)

A method according to claim 29 or claim 30 wherein the activated T cell population may have increased cytolytic activity relative to T cells activated with control immune cells.

### Claim 32 (depends on 24, 25, 26, 27, 28, 29, 30, 31)

A method according to any one of claims 24 to 31 wherein the FAMIN deficient immune cells have reduced FAMIN activity.

### Claim 33 (depends on 24, 25, 26, 27, 28, 29, 30, 31)

A method according to any one of claims 24 to 31 wherein the FAMIN deficient immune cells have no FAMIN activity.

### Claim 34 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A method according to any one of claims 24 to 33 wherein the immune cells are macrophages or dendritic cells.

### Claim 35 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A method according to any one of claims 24 to 34 wherein expression of active FAMIN polypeptide is reduced in the FAMIN deficient cells relative to control immune cells.

### Claim 36 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

A method according to any one of claims 24 to 35 wherein the FAMIN deficient cells display no expression of active FAMIN polypeptide.

### Claim 37 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

A method according to any one of claims 24 to 36 wherein the FAMIN deficient cells express a suppressor nucleic acid which reduces the expression of active FAMIN polypeptide

### Claim 38 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

A method according to any one of claims 24 to 36 wherein the FAMIN deficient cells comprise one or more mutations in the FAMIN gene which reduce the expression of active FAMIN polypeptide.

### Claim 39 (depends on 38)

A method according to claim 38 wherein the one or more mutations are insertions or deletions.

### Claim 40 (depends on 39)

A method according to claim 39 wherein the one or more mutations are introduced by targeted mutagenesis.

### Claim 41 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method according to any one of claims 24 to 40 wherein the population of FAMIN deficient immune cells is produced by a method comprising;
providing a population of immune cells obtained from a donor individual,
reducing FAMIN activity in the immune cells to produce a population of FAMIN deficient immune cells, and
culturing the FAMIN deficient immune cells.

### Claim 42 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method according to any one of claims 24 to 40 wherein the population of FAMIN deficient immune cells is produced by a method comprising;
providing a population of immune progenitor cells from sample obtained from a donor individual,
reducing FAMIN activity in the immune progenitor cells to produce a population of FAMIN deficient immune progenitor cells, and
differentiating the FAMIN deficient immune progenitor cells to produce a population of FAMIN deficient immune cells.

### Claim 43 (depends on 41, 42)

A method according to claim 41 or claim 42 wherein FAMIN activity is reduced by nucleic acid suppression.

### Claim 44 (depends on 43)

A method according to claim 43 wherein FAMIN activity is reduced by expressing in the immune cells or immune progenitor cells a suppressor nucleic acid which reduces the expression of active FAMIN polypeptide

### Claim 45 (depends on 41, 42)

A method according to claim 41 or claim 42 wherein FAMIN activity is reduced by targeted mutagenesis.

### Claim 46 (depends on 45)

A method according to claim 45 wherein FAMIN activity is reduced by expressing in the immune cells or immune progenitor cells a targeted nuclease which abolishes the expression of active FAMIN polypeptide

### Claim 47 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

A method according to any one of claims 24 to 46 wherein the T cells are CD8+ cytotoxic T cells.

### Claim 48 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

A method according to any one of claims 24 to 47 wherein the population of FAMIN deficient immune cells or T cells is administered in combination with a population of T cells to the individual.

### Claim 49 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A population of FAMIN deficient immune cells and/or population of T cells activated in vitro by a population FAMIN deficient immune cells for use in a method according to any one of claims 24 to 48.

### Claim 50

A pharmaceutical composition comprising a population of FAMIN deficient immune cells and/or a population of T cells activated by FAMIN deficient immune cells.

### Claim 51 (depends on 1, 2, 3, 4)

A method of screening for a compound useful in a method according to any one of claims 1 to 4 comprising;
determining the activity of an isolated FAMIN protein in the presence and absence of a test compound,
a decrease in the activity of a FAMIN protein in the presence relative to the absence of the test compound being indicative that the compound may be useful in said method.
